- PROGRAM
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
VersAptx™ Platform
VIP236
αvβ3 - optCPT SMDC
First-in-Class
First-in-Class
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
VIP943
Anti-CD123 - KSPi ADC
Best-in-Class
Best-in-Class
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
VIP924
Anti-CXCR5 - KSPi ADC
First-in-Class
First-in-Class
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
Anti-CD33 - KSPi ADC
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
Undisclosed Target 1 - KSPi ADC
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
Undisclosed Target 2 - KSPi ADC
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
P-TEFb Program
ENITOCICLIB
ENITOCICLIB* CDK9 inhibitor
Best-in-Class
Best-in-Class
- DISCOVERY
- PRECLINICAL
- PHASE 1
- PHASE 2
Next-Generation Adc Technology
Bioconjugation Platform
Antibody-drug conjugates (ADCs) are an established therapeutic approach in oncology used to selectively deliver potent cytotoxins directly to tumor cells, with the goal of maximizing toxicity in tumor cells, while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells.